Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase - PubMed (original) (raw)
. 2005 Jul 14;48(14):4596-607.
doi: 10.1021/jm0310986.
Isabelle Jeanclaude-Etter, Vittoria Ardissone, Steve Arkinstall, Yves Cambet, Montserrat Camps, Christian Chabert, Dennis Church, Rocco Cirillo, Denise Gretener, Serge Halazy, Anthony Nichols, Cedric Szyndralewiez, Pierre-Alain Vitte, Jean-Pierre Gotteland
Affiliations
- PMID: 15999997
- DOI: 10.1021/jm0310986
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase
Pascale Gaillard et al. J Med Chem. 2005.
Abstract
Several lines of evidence support the hypothesis that c-Jun N-terminal kinase (JNKs) plays a critical role in a wide range of diseases including cell death (apoptosis)-related disorders (neurodegenerative diseases, brain, heart, and renal ischemia, epilepsy) and inflammatory disorders (multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases). Screening of our internal compound collection for inhibitors of JNK3 led to the identification of (benzothiazol-2-yl)acetonitrile derivatives as potent and selective JNK1, -2, -3 inhibitors. Starting from initial hit 1 (AS007149), the chemistry and initial structure-activity relationship (SAR) of this novel and unique kinase inhibitor template were explored. Investigation of the SAR rapidly revealed that the benzothiazol-2-ylacetonitrile pyrimidine core was crucial to retain a good level of potency on rat JNK3. Therefore, compound 6 was further optimized by exploring a number of distal combinations in place of the chlorine atom. This led to the observation that the presence of an aromatic group, two carbons away from the aminopyrimidine moiety and bearing substituents conferring hydrogen bond acceptor (HBA) properties, could improve the potency. Further improvements to the biological and biopharmaceutical profile of the most promising compounds were performed, resulting in the discovery of compound 59 (AS601245). The in vitro and in vivo anti-inflammatory potential of this new JNK inhibitor was investigated and found to demonstrate efficacy per oral route in an experimental model of rheumatoid arthritis (RA).
Similar articles
- Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase.
Rückle T, Biamonte M, Grippi-Vallotton T, Arkinstall S, Cambet Y, Camps M, Chabert C, Church DJ, Halazy S, Jiang X, Martinou I, Nichols A, Sauer W, Gotteland JP. Rückle T, et al. J Med Chem. 2004 Dec 30;47(27):6921-34. doi: 10.1021/jm031112e. J Med Chem. 2004. PMID: 15615541 - AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties.
Carboni S, Hiver A, Szyndralewiez C, Gaillard P, Gotteland JP, Vitte PA. Carboni S, et al. J Pharmacol Exp Ther. 2004 Jul;310(1):25-32. doi: 10.1124/jpet.103.064246. Epub 2004 Feb 26. J Pharmacol Exp Ther. 2004. PMID: 14988419 - The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting.
Bogoyevitch MA. Bogoyevitch MA. Bioessays. 2006 Sep;28(9):923-34. doi: 10.1002/bies.20458. Bioessays. 2006. PMID: 16937364 Review. - Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.
Messoussi A, Feneyrolles C, Bros A, Deroide A, Daydé-Cazals B, Chevé G, Van Hijfte N, Fauvel B, Bougrin K, Yasri A. Messoussi A, et al. Chem Biol. 2014 Nov 20;21(11):1433-43. doi: 10.1016/j.chembiol.2014.09.007. Epub 2014 Oct 16. Chem Biol. 2014. PMID: 25442375 Review.
Cited by
- Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis.
Paunovic V, Harnett MM. Paunovic V, et al. Drugs. 2013 Feb;73(2):101-15. doi: 10.1007/s40265-013-0014-6. Drugs. 2013. PMID: 23371304 Review. - The selectivity of protein kinase inhibitors: a further update.
Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. Bain J, et al. Biochem J. 2007 Dec 15;408(3):297-315. doi: 10.1042/BJ20070797. Biochem J. 2007. PMID: 17850214 Free PMC article. - Increased operant responding for ethanol in male C57BL/6J mice: specific regulation by the ERK1/2, but not JNK, MAP kinase pathway.
Faccidomo S, Besheer J, Stanford PC, Hodge CW. Faccidomo S, et al. Psychopharmacology (Berl). 2009 May;204(1):135-47. doi: 10.1007/s00213-008-1444-9. Epub 2009 Jan 6. Psychopharmacology (Berl). 2009. PMID: 19125235 Free PMC article. - Inhibitors of c-Jun N-terminal kinases: JuNK no more?
Bogoyevitch MA, Arthur PG. Bogoyevitch MA, et al. Biochim Biophys Acta. 2008 Jan;1784(1):76-93. doi: 10.1016/j.bbapap.2007.09.013. Epub 2007 Oct 11. Biochim Biophys Acta. 2008. PMID: 17964301 Free PMC article. Review. - Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.
Kamenecka T, Jiang R, Song X, Duckett D, Chen W, Ling YY, Habel J, Laughlin JD, Chambers J, Figuera-Losada M, Cameron MD, Lin L, Ruiz CH, LoGrasso PV. Kamenecka T, et al. J Med Chem. 2010 Jan 14;53(1):419-31. doi: 10.1021/jm901351f. J Med Chem. 2010. PMID: 19947601 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials
Miscellaneous